YOLFTbeta
CRISM Therapeutics Corporation

CRISM Therapeutics Corporation

CRTX · LSE · Healthcare / Biotechnology

8.25GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close8.25
Open8.01
Day Range8.00 – 8.50
52-Week Range8.00 – 18.50
Volume23.18K
Market Cap7.32M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.05
Dividend Yield0.00%
Beta0.58
50-Day Avg10.42
200-Day Avg11.29

About

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM Therapeutics Corporation is based in Road Town, the British Virgin Islands.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ae Jack Swanson
  • Employees0
  • HeadquartersKingston Chambers, Road Town, British Virgin Islands, UK
  • Websitehttps://www.crismtherapeutics.com

Leadership

  • Mr. Ae Jack SwansonChief Operating Officer · b. 1938

Financials

Income Statement

Currency: GBP2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----------------0056.88K19.98K231.00K
Growth (%)---------------------64.88%+1056.33%
Cost of Revenue3.32K7.99K9.57K566.90K868.33K878.97K190.31K153.70K----1.82K6.26K4.75K4.70K5.30K--60.67K3.20K117.00K
Gross Profit-3.32K-7.99K-9.57K-566.90K-868.33K-878.97K-190.31K-153.70K-----1.82K-6.26K-4.75K-4.70K-5.30K---3.79K16.78K-117.00K
Gross Margin--------------------6.67%84.00%-50.65%
Operating Expense1.08M1.41M1.62M1.22M1.17M553.35K1.31M2.65M----3.77M1.92M2.15M1.55M3.08M--212.93K481.85K1.99M
Operating Income-1.08M-1.42M-1.63M-1.78M-2.03M-1.43M-1.50M-2.81M-1.87M-2.49M-2.36M-3.97M-3.77M-1.92M-2.15M-1.56M-3.08M-1.79M-2.22M-216.72K-465.07K-2.11M
Operating Margin--------------------381.01%-2328.03%-912.99%
EBITDA-4.64M-1.41M-1.62M-1.78M-2.02M-1.20M-1.31M-2.65M-1.87M-2.17M-1.82M-3.97M-3.43M-2.12M-2.15M-1.10M-3.08M-1.75M-1.95M-2.08M-452.28K-2.09M
EBITDA Margin--------------------3663.85%-2264.02%-905.63%
Net Income-4.64M-1.48M-1.60M-1.97M-2.23M-1.81M365.60K-4.45M-4.05M-3.76M-1.36M-683.63K-5.25M-1.20M-3.14M-1.83M-2.83M-1.54M-2.45M-247.74K-485.05K-1.90M
Net Income Margin--------------------435.56%-2428.03%-823.81%
R&D-------------------40.79K134.25K908.00K
R&D as % of Total Revenue-------------------71.72%672.01%393.07%
Interest Expense------5.01K-------1.16M723.00K13.00K0-40.45K8.79K0
Interest Expense % of Total Revenue-------------------71.11%44.00%0.00%

Balance Sheet

Currency: GBP2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--9.35M6.71M11.07M16.81M21.40M21.29M16.19M18.13M21.13M15.91M29.43M29.14M26.24M21.34M32.40M31.24M23.89M160.53K1.82M1.80M
Total Liabilities--15.71K175.32K292.12K289.43K109.60K102.00K73.21K74.25K407.00K709.20K3.88M944.00K2.76M852.24K1.05M1.13M765.65K920.19K341.00K381.00K
Total Equity--9.33M6.53M10.78M16.52M21.55M13.63M16.12M18.05M20.72M15.21M25.75M28.38M23.62M20.48M31.35M30.11M23.13M4.12M1.48M1.42M
Cash--3.00M1.73M441.83K997.63K1.96M2.85M1.26M1.44M890.81K6.51M8.20M2.56M1.26M385.09K2.79M4.93M2.90M1.26K1.28M1.13M
Total Debt--------------1.66M----496.75K--
Net Debt---3.00M-1.73M-441.83K-617.39K-1.96M-2.85M-1.26M-1.44M-890.81K-6.51M-8.14M-2.54M406.00K-385.09K-2.79M-4.93M-2.90M495.49K-1.28M-1.13M

Cash Flow

Currency: GBP2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.10M-998.08K-692.47K-2.06M-843.95K-778.08K-2.67M-750.98K-1.62M-1.96M-2.99M-2.01M-2.70M-2.46M-1.90M-2.28M-1.83M-3.52M-2.77M-933.00K-1.97M
Investing Cash Flow-2.23M-1.34M-2.57M-3.29M-202.99K-83.18K-19.33K-2.20M-2.41M-747.86K-1.86M-4.12M-3.70M-1.95M-500.00K-5.18M6.04M-511.00K34.93M2.33M-31.00K
Financing Cash Flow5.14M2.83M2.65M4.45M1.40M2.29M4.20M1.37M4.41M1.84M13.95M5.99M570.00K3.28M1.50M9.89M-968.00K-31.45M-67.00K1.84M
Capital Expenditure7.77K1.32M2.64M3.33M328.98K318.54K1.21M437.34K72.79K747.86K590.68K4.12M3.87M1.95M392.71K439.81K426.00K265.47K12.00K28.00K31.00K
Free Cash Flow-1.11M-2.32M-3.34M-5.39M-1.17M-1.10M-3.88M-1.19M-1.69M-2.71M-3.58M-6.13M-6.69M-4.40M-1.88M-2.12M-2.26M-2.99M-2.77M-961.00K-1.97M
Dividends Paid------------------31.45M47.00K-
FCF to OCF100.71%232.53%481.73%261.40%138.98%140.94%145.49%158.24%104.50%138.16%119.74%305.49%247.32%179.34%98.99%92.77%123.24%85.11%100.00%103.00%100.00%
Dividend Paid to FCF-------------------1135.27%-4.89%-

Earnings

Report DateSep 19, 2024Sep 15, 2025
EPS Estimate0.000.00
EPS Actual0.00-0.03
Surprise--
Timing--

Key Statistics & Ratios

Market Cap7.32M
Enterprise Value6.44M
Trailing P/E0.00
Forward P/E0.00
Price / Sales20.81
Price / Book2.99
EPS-0.05
Book Value0.033
Revenue (TTM)352.00K
Gross Profit (TTM)226.00K
EBITDA-2.38M
Profit Margin0.00%
Operating Margin-1180.17%
Return on Equity-122.71%
Return on Assets-64.37%
Shares Outstanding79.19M
Shares Float79.14M
Beta0.58
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
2.88Jun 1, 2023

Stock Splits

  • May 31, 20241:160